| Sign In | Join Free | My infospaceinc.com |
|
| Categories | THROBIO |
|---|---|
| Payment Terms: | T/T |
| Administrationroute: | Intravenous |
| Indications: | Acute ischemic stroke, acute myocardial infarction, pulmonary embolism |
| Supply Ability: | 100000 |
| Activeingredient: | Recombinant Tissue Plasminogen Activator (rt-PA) |
| Approvalstatus: | Approved by relevant health authorities |
| Model Number: | TRPCL |
| Sideeffects: | Bleeding, allergic reactions, hypotension |
| Mechanismofaction: | Converts plasminogen to plasmin to dissolve blood clots |
| Packaging Details: | VIALS PACKING |
| Contraindications: | Active internal bleeding, recent surgery, hemorrhagic stroke |
| MOQ: | 1 |
| Delivery Time: | 3-5 DAYS |
| Manufacturer: | THROBIO |
| Type: | Biological Thrombolytic Agent |
| Price: | 500USD |
| Dosageform: | Injection |
| Shelflife: | 24 months |
| Brand Name: | THROBIO |
| Productname: | THROBIO |
| Certification: | ISO13485 GMP FDA |
| Storageconditions: | 2-8°C, protect from light |
| Place of Origin: | USA |
| Precautions: | Monitor for signs of bleeding, use with caution in elderly patients |
| Company Info. |
| Guangdong Fitakh Pharmaceutical Biotechnology Co., Ltd. |
| Verified Supplier |
| View Contact Details |
| Product List |
Parameter Item | Specification Standard |
Chemical Name | Polycaprolactone (PCL) |
Product Purity | ≥98% Medical Implant Grade |
Microsphere Particle Size | 20–50 μm Uniform High-sphericity Particles |
Molecular Weight | 30000–80000 Da |
Formula Composition | PCL Microspheres + Biodegradable CMC Gel |
In-vivo Degradation Cycle | 24–30 Months Ultra-long Stable Effect |
Metabolite | Carbon Dioxide & Water, Zero Residue, No Acid Accumulation |
Biocompatibility Standard | ISO 10993 Full Medical Certification |
Core Advantages | Ultra-mild degradation, low inflammation, ultra-long efficacy,
natural collagen regeneration |
|